DK1017371T3 - Kontrolleret frigivelse af sublingualt eller bukalt indgivne lægemidler - Google Patents

Kontrolleret frigivelse af sublingualt eller bukalt indgivne lægemidler

Info

Publication number
DK1017371T3
DK1017371T3 DK98919989T DK98919989T DK1017371T3 DK 1017371 T3 DK1017371 T3 DK 1017371T3 DK 98919989 T DK98919989 T DK 98919989T DK 98919989 T DK98919989 T DK 98919989T DK 1017371 T3 DK1017371 T3 DK 1017371T3
Authority
DK
Denmark
Prior art keywords
sublingually
controlled release
administered drugs
buccally administered
buccally
Prior art date
Application number
DK98919989T
Other languages
English (en)
Inventor
Ragab El-Rashidy
Bruce Ronsen
Emad Eldin Hassan
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1017371T3 publication Critical patent/DK1017371T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98919989T 1997-04-29 1998-04-29 Kontrolleret frigivelse af sublingualt eller bukalt indgivne lægemidler DK1017371T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/841,250 US5888534A (en) 1995-06-13 1997-04-29 Controlled release of drugs delivered by sublingual or buccal administration
PCT/US1998/008630 WO1998048781A1 (en) 1997-04-29 1998-04-29 Controlled release of drugs delivered by sublingual or buccal administration

Publications (1)

Publication Number Publication Date
DK1017371T3 true DK1017371T3 (da) 2003-09-29

Family

ID=25284405

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98919989T DK1017371T3 (da) 1997-04-29 1998-04-29 Kontrolleret frigivelse af sublingualt eller bukalt indgivne lægemidler

Country Status (22)

Country Link
US (1) US5888534A (da)
EP (1) EP1017371B1 (da)
JP (1) JP4948691B2 (da)
CN (1) CN1135103C (da)
AR (1) AR012615A1 (da)
AT (1) ATE244000T1 (da)
BR (1) BR9808703A (da)
CA (1) CA2289260C (da)
CO (1) CO4940397A1 (da)
CZ (1) CZ292513B6 (da)
DE (1) DE69816103T2 (da)
DK (1) DK1017371T3 (da)
ES (1) ES2201487T3 (da)
HU (1) HU225108B1 (da)
IL (1) IL132646A0 (da)
NO (1) NO995302L (da)
NZ (1) NZ501114A (da)
PL (1) PL336759A1 (da)
PT (1) PT1017371E (da)
TW (1) TW430562B (da)
WO (1) WO1998048781A1 (da)
ZA (1) ZA983548B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6291471B1 (en) 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
BR0109515A (pt) 2000-04-07 2004-08-10 Tap Pharmaceutical Prod Inc Derivados da apomorfina e métodos para seu uso
US6528521B2 (en) * 2000-11-15 2003-03-04 Tap Pharmaceutical Products, Inc. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
JP2004520389A (ja) * 2001-02-08 2004-07-08 ファルマシア・コーポレーション 性的不全の治療のための早期効果発現薬剤
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20060073174A1 (en) * 2001-08-16 2006-04-06 Access Pharmaceuticals, Inc. Adherent and erodible film to treat a moist surface of a body tissue
ES2426723T3 (es) * 2001-10-17 2013-10-24 Takeda Pharmaceutical Company Limited Gránulos que contienen gran cantidad de compuesto químico inestable en medio ácido
PL372290A1 (en) * 2002-02-07 2005-07-11 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
KR20050008658A (ko) * 2002-03-19 2005-01-21 마이클 홀릭 아포모르핀의 글리코시드 및 오르토에스테르 글리코시드유도체들, 유사체들 및 그것의 용도
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
US8221792B2 (en) * 2005-07-07 2012-07-17 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
US20070020186A1 (en) * 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
JP2009149524A (ja) * 2006-03-16 2009-07-09 Kyushu Univ アルツハイマー病の予防・治療剤
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
CN102056568B (zh) 2008-06-04 2013-08-21 高露洁-棕榄公司 具有气穴系统的口腔护理器具
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
CN101475145B (zh) * 2009-01-20 2014-10-22 同济大学 一种具有磁热和靶向药物缓释特性的水滑石及其制备方法
PT2952191T (pt) * 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
AU2010290795B2 (en) * 2009-09-04 2015-12-10 Munisekhar Medasani Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same
BR112012012945A2 (pt) 2009-11-25 2020-12-29 Arisgen Sa Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
NZ612686A (en) * 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
SMT202100546T1 (it) 2011-09-19 2021-11-12 Orexo Ab Compresse per via sublinguale resistenti all'abuso comprendenti buprenorfina e naloxone
US20140256822A1 (en) * 2013-03-11 2014-09-11 Pharmaceutical Productions Inc. Transmucosal drug delivery system
JP7211706B2 (ja) 2015-04-21 2023-01-24 サノヴィオン ファーマシュティカルズ インコーポレーテッド 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法
EP3554489A4 (en) 2016-12-15 2020-06-17 Evoke Pharma, Inc. TREATMENT FROM MODERATE TO HEAVY GASTROPARESIS
US12589095B2 (en) 2019-05-31 2026-03-31 Primo Pharmatech Llc Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient
WO2021231860A1 (en) * 2020-05-14 2021-11-18 Primo Pharmatech Llc Solid dosage form for transmucosal drug delivery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US3428728A (en) * 1965-10-21 1969-02-18 Hans Lowey Timed release sublingual medications
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
JP3310982B2 (ja) * 1994-04-22 2002-08-05 ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド 男性の勃起機能不全を改善するための剤形及び方法
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions

Also Published As

Publication number Publication date
HUP0003405A3 (en) 2001-04-28
CA2289260C (en) 2008-02-12
BR9808703A (pt) 2001-11-20
NO995302D0 (no) 1999-10-29
EP1017371A1 (en) 2000-07-12
HK1031334A1 (en) 2001-06-15
IL132646A0 (en) 2001-03-19
DE69816103T2 (de) 2004-04-15
EP1017371A4 (en) 2000-07-12
EP1017371B1 (en) 2003-07-02
CN1271276A (zh) 2000-10-25
HU225108B1 (en) 2006-06-28
NZ501114A (en) 2001-09-28
ES2201487T3 (es) 2004-03-16
US5888534A (en) 1999-03-30
AR012615A1 (es) 2000-11-08
JP2001527546A (ja) 2001-12-25
NO995302L (no) 1999-12-27
HUP0003405A2 (hu) 2001-02-28
ZA983548B (en) 1999-01-28
TW430562B (en) 2001-04-21
PL336759A1 (en) 2000-07-17
WO1998048781A1 (en) 1998-11-05
CO4940397A1 (es) 2000-07-24
ATE244000T1 (de) 2003-07-15
CN1135103C (zh) 2004-01-21
CZ292513B6 (cs) 2003-10-15
JP4948691B2 (ja) 2012-06-06
DE69816103D1 (de) 2003-08-07
CA2289260A1 (en) 1998-11-05
PT1017371E (pt) 2003-10-31
CZ386099A3 (cs) 2000-04-12

Similar Documents

Publication Publication Date Title
DK1017371T3 (da) Kontrolleret frigivelse af sublingualt eller bukalt indgivne lægemidler
ID27040A (id) Bentuk sediaan dengan pelepasan berpulsa dari bahan farmasi oral
DK1041972T3 (da) Tablet til øjeblikkelig og prolongeret release af ét eller flere aktive stoffer
EP1019100A4 (en) TAXED ACTIVE SUBSTITUTES
IS5245A (is) Lyfjablanda úr ómeprasól
DK1043976T3 (da) Oral farmaceutisk doseringsform med langvarig frigivelse
ATE253371T1 (de) Formulierungen von clarithromycin mit verlängerter wirkstoff-freisetzung
DK200200116U4 (da) Mundhygiejnepræparat til behandling af halitosis
NO996133D0 (no) Olje-i-vann-vaksinesammensetninger
DK0922386T3 (da) Sammensætninger med reguleret frigivelse
NO995753D0 (no) Gastroretarderende mikrosfaerer med styrt frigivelse for bedret administrasjon av medikament
DK0875252T3 (da) Formuleringer af aktiveret protein C
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
DK0880892T3 (da) Midler med reguleret frigivelse
DE69829254D1 (de) Arzneistoffzubereitung mit kontrollierter Wirkstofffreisetzungsrate
DE69816760D1 (de) Trennfolie
NO20001375D0 (no) Legemiddelformulering med kontrollert virkestoffrigivning
NO20002126D0 (no) Formulering med forlenget frigjøring
NO995251D0 (no) FremgangsmÕte for administrering av haloterapi
DE69703368D1 (de) Silikontrennfilm
DE69807768D1 (de) Rapamycin enthaltende Formulierungen zur oralen Verabreichung
EE03511B1 (et) Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid
FI974001A0 (fi) Nya metylenbisfosfonsyraderivat
NO994140D0 (no) Farmasöytisk sammensetning for den programerte frigivelse av deksfenfluramin
KR980004079U (ko) 적외선 투사기의 안전망 착탈구조